In an immunocompetent adult with genital herpes, what are the recommended valacyclovir dosing regimens for an initial outbreak, recurrent episodes, daily suppressive therapy, and how should the dose be adjusted for creatinine clearance less than 50 mL/min?

Valacyclovir Dosing for Genital Herpes in Immunocompetent Adults

For an initial outbreak of genital herpes, prescribe valacyclovir 1 gram orally twice daily for 10 days, starting within 48 hours of symptom onset for maximum efficacy. 1

Initial Episode Treatment

• Valacyclovir 1 gram orally twice daily for 10 days is the FDA-approved regimen for first-episode genital herpes. 1
• Therapy is most effective when initiated within 48 hours of the onset of signs and symptoms. 1
• Alternative regimens include acyclovir 400 mg orally three times daily for 7–10 days or acyclovir 200 mg orally five times daily for 7–10 days. 2
• Do not use short-course therapy (1,2, or 3 days) for initial episodes—these abbreviated regimens are inappropriate for first presentations. 3

Recurrent Episodes (Episodic Therapy)

• Valacyclovir 500 mg orally twice daily for 3 days is the FDA-approved episodic regimen for recurrent genital herpes. 1
• Initiate treatment at the very first sign of prodrome (tingling, burning, itching) or within 24 hours of lesion appearance to achieve maximal benefit. 2, 4
• Provide patients with a standing prescription or medication supply so they can self-initiate therapy immediately when symptoms begin. 2, 4
• Starting episodic therapy more than 24 hours after symptom onset markedly reduces efficacy. 2

Alternative Episodic Regimens

• Acyclovir 400 mg orally three times daily for 5 days or acyclovir 200 mg orally five times daily for 5 days are acceptable alternatives, though they require more frequent dosing. 2
• Famciclovir 500 mg orally twice daily for 3 days is another effective option. 2

Daily Suppressive Therapy

Valacyclovir 1 gram orally once daily is the standard suppressive regimen for immunocompetent adults with frequent recurrences. 1, 5

Indications for Suppressive Therapy

• Consider daily suppressive therapy when a patient experiences ≥6 recurrences per year. 2, 6
• Suppressive therapy is also appropriate for patients with severe episodes, significant psychological distress, or those wishing to reduce transmission risk to partners. 2, 6

Dosing Options Based on Recurrence Frequency

• For patients with ≤9 recurrences per year: Valacyclovir 500 mg orally once daily is an acceptable alternative dose. 1, 5
• For patients with ≥10 recurrences per year: Valacyclovir 1 gram orally once daily provides superior suppression. 5
• Daily suppressive therapy reduces recurrence frequency by ≥75%. 2, 6

Duration and Reassessment

• Continuous use of valacyclovir has been documented as safe for up to 1 year. 2
• After 1 year of suppressive therapy, reassess the need for continuation because recurrence frequency often declines over time in many patients. 2, 6
• Consider a trial off therapy to determine whether ongoing suppression remains necessary. 6

Important Counseling Points

• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding, and transmission can still occur even without visible lesions. 2, 4
• Partners should be informed that zero transmission risk does not exist, even while on suppressive therapy. 6

Dose Adjustment for Renal Impairment (Creatinine Clearance <50 mL/min)

Renal function must be assessed before initiating valacyclovir in all patients, especially those aged ≥80 years, to prevent drug accumulation and neurotoxicity. 6, 1

Dosing Adjustments by Indication and Creatinine Clearance

Indication	CrCl 30–49 mL/min	CrCl 10–29 mL/min	CrCl <10 mL/min
Initial episode (1 g twice daily)	No reduction	1 g every 24 hours	500 mg every 24 hours
Recurrent episodes (500 mg twice daily)	No reduction	500 mg every 24 hours	500 mg every 24 hours
Suppressive therapy (1 g once daily)	No reduction	500 mg every 24 hours	500 mg every 24 hours
Suppressive therapy (500 mg once daily, ≤9 recurrences/year)	No reduction	500 mg every 48 hours	500 mg every 48 hours

1

Hemodialysis Patients

• Administer the recommended dose of valacyclovir after hemodialysis. 1
• Approximately one-third of acyclovir is removed during a 4-hour hemodialysis session. 1

Peritoneal Dialysis Patients

• Supplemental doses of valacyclovir are not required following continuous ambulatory peritoneal dialysis (CAPD) or continuous arteriovenous hemofiltration/dialysis (CAVHD). 1

Special Considerations for HIV-Infected Patients

• For HIV-infected patients with CD4+ count ≥100 cells/mm³: Valacyclovir 500 mg orally twice daily is the recommended suppressive regimen. 3, 1
• HIV-infected patients should receive 5–14 days of treatment for acute genital herpes episodes (not the abbreviated 3-day regimen used in immunocompetent hosts). 3
• Short-course therapy (1,2, or 3 days) should never be used in HIV-infected patients. 3

Management of Severe or Complicated Disease

• For severe mucocutaneous HSV lesions requiring hospitalization or disseminated disease: Initiate IV acyclovir 5–10 mg/kg every 8 hours until lesions begin to regress, then switch to oral therapy and continue until complete healing. 3, 4
• Monitor renal function and adjust dosing at initiation and once or twice weekly during IV acyclovir therapy. 3

Treatment Failure and Acyclovir Resistance

• Suspect acyclovir resistance if lesions do not begin to resolve within 7–10 days of therapy. 3
• Obtain viral culture and susceptibility testing to confirm resistance. 3
• For confirmed acyclovir-resistant HSV: IV foscarnet 40 mg/kg every 8 hours until clinical resolution is the treatment of choice. 3, 4
• All acyclovir-resistant strains are also resistant to valacyclovir. 4
• Resistance rates are higher in immunocompromised patients (approximately 7%) compared with immunocompetent hosts (<0.5%). 6

Common Pitfalls to Avoid

• Do not delay episodic treatment—starting therapy more than 24 hours after symptom onset markedly reduces efficacy. 2
• Avoid topical antivirals—topical acyclovir is substantially less effective than oral therapy and should not be used for genital HSV. 2, 6
• Do not use short-course regimens in HIV-infected patients—these individuals require 5–14 days of therapy for acute episodes. 3
• Do not prescribe valacyclovir 8 grams per day in immunocompromised patients—this high dose is associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. 4, 7
• Do not fail to assess renal function before initiating therapy, especially in elderly patients (≥80 years), to prevent neurotoxicity from drug accumulation. 6, 1

Adverse Events and Monitoring

• Valacyclovir is generally well-tolerated, with the most common side effects being headache (<10%), nausea (<4%), and diarrhea, which are typically mild to moderate. 6
• No laboratory monitoring is needed in patients with normal renal function receiving episodic or suppressive therapy. 3
• For patients with substantial renal impairment, monitor renal function and adjust dosing accordingly. 3, 1